glp-1 obesity drug news updates Alarming rise in weight loss overdoses Weight loss with GLP-1 medicines
Description
Dual- and multi-receptor agonists may be a novel drug class to treat obesity and type 2 diabetes mellitus with high efficacy.
A new blockbuster class of therapeutics, glucagon-like peptide 1 (GLP-1) analogs (eg, semaglutide), shows promise at curbing both diseases
Other adverse effects, including depression, sleep disturbances, and anxiety, have also been noted.While these side effects are usually transient, they can be bothersome enough to prompt some patients to discontinue treatment prematurely
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been studied for their cardiovascular benefits in type 2 diabetes
